Acneiform Eruption Induced by Dacomitinib (PF-00299804) / 대한피부과학회지
Korean Journal of Dermatology
;
: 324-327, 2015.
Artículo
en Coreano
| WPRIM
| ID: wpr-135049
ABSTRACT
Dacomitinib (PF-00299804) is a newly developed irreversible pan-HER (human epidermal growth factor receptor) inhibitor for the treatment of non-small cell lung cancer (NSCLC). Inhibiting HER-1 (epidermal growth factor receptor, EGFR), HER-2, and HER-4 may induce similar cutaneous side effects to those of traditional EGFR inhibitors. We report two patients who developed acneiform eruption on the face and trunk, induced by dacomitinib treatment for NSCLC. The skin lesions appeared 3~4 weeks after the initiation of dacomitinib use, and they improved after oral minocycline and topical clindamycin treatment. There has been no report of acneiform eruption after dacomitinib treatment in Korean dermatology journals.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Piel
/
Clindamicina
/
Erupciones Acneiformes
/
Carcinoma de Pulmón de Células no Pequeñas
/
Dermatología
/
Quimioterapia
/
Factor de Crecimiento Epidérmico
/
Minociclina
Límite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Dermatology
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS